Clinical trial • Phase III • Neurology|Rare Disease
Clinical trial in Huntington's disease
Phase III trial for Huntington's disease. 27 participants.
Overview
- Trial Therapeutic Area
- Neurology|Rare Disease
- Trial Disease
- Huntington's disease
- Trial Stage
- Phase III
- Drug Modality
- Radiopharmaceutical
Key dates
- Initial CTIS Submission Date
- 11-12-2024
- First CTIS Authorization Date
- 17-12-2024
Trial design
Phase III trial across 1 site in Belgium.
- Target Sample Size
- 27
Recruitment
- Planned Sample Size
- 27
- Recruitment Window Months
- 36
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 27
Belgium
- Earliest CTIS Part Ii Submission Date
- 11-12-2024
- Latest Decision Or Authorization Date
- 29-01-2026
- Processing Time Days
- 414
- Number Of Sites
- 1
- Number Of Participants
- 27
Sites
- Site Name
- UZ Leuven
- Department Name
- Department of Neurology
- Principal Investigator Name
- Wim Vandenberghe
- Principal Investigator Email
- wim.vandenberghe@uzleuven.be
- Contact Person Name
- Wim Vandenberghe
- Contact Person Email
- wim.vandenberghe@uzleuven.be
- Number Of Participants
- 27
Sponsor
Primary sponsor
- Full Name
- CHDI Foundation Inc.
- Organisation Type
- Patient organisation/association
- Country Of Registered Address
- United States
Related trials
Other published trials that may interest you.